Posted 25th May 2018 by Kieran Chambers
Process intensification and continuous biomanufacturing continue to attract a lot of interest within the biopharmaceutical industry as a method that can increase productivity and make the most efficient use of production assets.
Posted 23rd May 2018 by Kieran Chambers
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
Over the course of the Global NASH Congress, 40 expert-led presentations and interactive roundtable discussions explored these key issues. If you were unable to attend, please enjoy these free slides from Eric Hughes, Jon Reik and Pierre Bedossa.
Posted 21st May 2018 by Anna Gomez
An inquiry by the House of Lords’ Science & Technology Committee has identified several issues that could hamper the delivery of the Life Sciences Industrial Strategy vision1. The critical report (Life Sciences Industrial Strategy: Who’s driving the bus? 1) brings together evidence from industry, academia and the NHS. It highlights several implementation challenges which require “prompt and vigorous action by the government” to ensure that the scope of Life Sciences Industrial Strategy can be achieved.
Posted 18th May 2018 by Kieran Chambers
Before tackling the question of why everyone thinks drugging RNA is so hard, one might ask why drugging proteins is considered to be so easy (at least by comparison). Put differently, why were proteins first?
Posted 16th May 2018 by Kate Barlow
Companies typically approach contract research companies with the aim to better understand single organisms, groups of organisms, metabolic pathways and the interaction with the host that make up the microbiome. In addition, companies search for compounds or modulators that could improve in the end the healthy state of the host. Such modulators could be prebiotics, probiotics, enzyme inhibitors, antimicrobials and more.
NIZO is an independent contract research company that works on proteins, bacteria and processing on behalf of their global client base in food and pharma. Their unique business model centres around performing industrially relevant research projects for the industry under strict confidentiality and with clear IP clauses.
Posted 14th May 2018 by Anna Gomez
Our understanding of the aberrant biological pathways (oncogenic pathways) that are involved in the formation and progression of cancers has increased with huge leaps in the last decades of cancer research. The ever-increasing knowledge was and still is accompanied by the development of increasing numbers of precision drugs, tailored to neutralize these aberrations.
Posted 9th May 2018 by Kieran Chambers
Bioprocesses are traditionally performed in (fed-) batch processes for the production of various recombinant proteins and therapeutics. Batch processing comprises of processes where the material flow has hold steps in between two unit operations where the product is recovered from each unit operation step. However, such batch processes are attributed to longer process time and costs, and inconsistent process performance.
Posted 3rd May 2018 by Gaspar Taroncher-Oldenburg
The opportunity afforded by the microbiome for developing therapeutic and wellness products is matched only by the formidable task of unraveling the science of the microbiome in the first place. Microbiome research is transitioning from a descriptive to a more mechanistic science, and progress in understanding mechanisms that underpin microbiome biology is likely to result in a surge of interest in this space on the part of the biotech, pharma and investor communities.